A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.

scientific article

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3350/CMH.2012.18.3.272
P932PMC publication ID3467430
P698PubMed publication ID23091807
P5875ResearchGate publication ID232612252

P2093author name stringBoo Sung Kim
Hong Soo Kim
Jae Young Jang
Sang Gyune Kim
Soung Won Jeong
Young Seok Kim
Se Whan Lee
Se Hun Kim
Yu Ri Seo
Seung Sik Park
Byung Chul You
Hun il Kim
P2860cites work[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].Q50567373
[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].Q50568914
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.Q50583979
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.Q50588396
Ribavirin Quantification in Combination Treatment of Chronic Hepatitis CQ27473304
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionQ27860901
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialQ27860949
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupQ27861083
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseQ29547886
Diagnosis, management, and treatment of hepatitis C: an updateQ29619682
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agentsQ33388340
Global challenges in liver diseaseQ33999114
Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinomaQ34656178
Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotypeQ34657963
Optimal therapy of hepatitis C.Q34984079
Epidemiology of hepatitis C virus in KoreaQ36258725
Current status of liver disease in Korea: hepatitis C.Q37663502
Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis CQ38501611
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.Q42608962
Antiviral action of ribavirin in chronic hepatitis C.Q42983488
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.Q42990082
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rateQ42999332
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirinQ43032187
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatmentQ43034816
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.Q43035939
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Q43040369
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trialQ43040967
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferonQ43048289
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentQ44901526
Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in KoreaQ45076673
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IQ45752944
Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.Q46866205
Differences in treatment outcome for hepatitis C among ethnic groupsQ46920864
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue3
P921main subjectribavirinQ421862
pegylated interferonQ7160835
virologyQ7215
P304page(s)272-278
P577publication date2012-09-25
P1433published inClinical and molecular hepatologyQ26853927
P1476titleA reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
P478volume18

Reverse relations

Q37098107The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.cites workP2860

Search more.